A Medical Device Daily

Biofisica (Duluth, Georgia) a company specializing in wound-care therapy, reported that it has obtained a commitment of $2.3 million in financing from investors.

The company, which was founded in 2000, said the funding will support its continued marketing efforts in the UK and ongoing planning initiatives in the U.S.

The round was led by Unilever Technology Ventures, Novartis Venture Funds and the ATDC Seed Capital Fund, as well as a number of private investors.

POSiFECT combines two technologies — moist wound-care dressing and electrical stimulation — in a disposable, sterile dressing that is designed to facilitate the normal healing process. The company said that clinical research has shown that POSiFECT accelerates healing in difficult-to-heal or non-healing chronic wounds.

The product, which is not yet available in the U.S., was launched last year in the UK. It also has been approved for marketing in Canada.

"We believe that Biofisica's POSiFECT technology represents an innovative and effective approach to the treatment of chronic wounds," said Dion Madsen, managing director of Physic Ventures, the general partner for Unilever Technology Ventures.

"Chronic wounds are poorly treated and this technology approach represents a convenient and cost-effective therapy that has the potential to improve the lives of millions of chronic wound-care patients."